Active, not recruitingNCT07232719ClinicalTrials.gov record

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

Obesity · Overweight

Ask WCR about this study Official registry record ↗

THE QUICK READ

What this study involves

The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.

Study type: Interventional
Phase: Phase 3
Age range: 18 years - Not specified
Sex eligible: All sexes
Healthy volunteers: Not accepted
Participants: 250 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.

Participation in the study will last about 65 weeks and may include about 18 visits.

Participants who complete the primary 56-week GZQJ study will have the opportunity to receive an additional 52 weeks of treatment with retatrutide.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

Have a body mass index (BMI) of:

≥30 kilogram per square meter (kg/m2) OR
≥27 kg/m2 with at least one of the following weight-related conditions: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease
Have at least one unsuccessful attempt to lose weight by dieting

Exclusion Criteria:

Have a self-reported change in body weight \>5 kg (11 pounds) within 90 days before screening
Have a prior or planned surgical treatment for obesity
Have type 1 diabetes or type 2 diabetes
Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
Have had within the past 90 days before screening

acute myocardial infarction
cerebrovascular accident (stroke)
hospitalization for unstable angina, or
hospitalization due to congestive heart failure
Have New York Heart Association Functional Classification Class IV congestive heart failure
Have a history of chronic or acute pancreatitis
Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening

Understand screening

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment: Random assignment
Masking: Double masked

Retatrutide Dose 1

Participants will receive retatrutide subcutaneously (SC)

Drug: Retatrutide

Retatrutide Dose 2

Participants will receive retatrutide SC

Drug: Retatrutide

Placebo

Participants will receive placebo SC

Drug: Placebo

Retatrutide DRUG

Administered SC

Placebo DRUG

Administered SC

Prepare your questions

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.